Healthdirect Free Australian health advice you can count on.
Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately
healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.
NSW Health Alert: Any patients who have received dental treatment from Mr Safuan (Steven) Hasic at 70 Victoria Ave, Mortdale NSW 2223 may
be at risk of blood-borne viruses and should see their GP for precautionary testing. More information is available from
NSW Health
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
OPSUMIT, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of:
idiopathic pulmonary arterial hypertension
heritable pulmonary arterial hypertension
pulmonary arterial hypertension associated with connective tissue disease
pulmonary arterial hypertension associated with congenital heart disease with repaired shunts in patients with WHO Functional class II, III or IV symptoms.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OPSUMIT, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of:
idiopathic pulmonary arterial hypertension
heritable pulmonary arterial hypertension
pulmonary arterial hypertension associated with connective tissue disease
pulmonary arterial hypertension associated with congenital heart disease with repaired shunts in patients with WHO Functional class II, III or IV symptoms.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OPSUMIT, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of:
idiopathic pulmonary arterial hypertension
heritable pulmonary arterial hypertension
pulmonary arterial hypertension associated with connective tissue disease
pulmonary arterial hypertension associated with congenital heart disease with repaired shunts in patients with WHO Functional class II, III or IV symptoms.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OPSUMIT, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of:
idiopathic pulmonary arterial hypertension
heritable pulmonary arterial hypertension
pulmonary arterial hypertension associated with connective tissue disease
pulmonary arterial hypertension associated with congenital heart disease with repaired shunts in patients with WHO Functional class II, III or IV symptoms.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Dispersible tablets,Paediatric (2 years to less than 18 years of age),OPSUMIT, as monotherapy or in combination, is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease, pulmonary arterial hypertension associated with congenital heart disease with repaired shunts, pulmonary arterial hypertension with co-incidental congenital heart disease,in paediatric patients with WHO Functional class I, II, III or IV symptoms.,See section 4.2 DOSE AND METHOD OF ADMINISTRATION, Dosage, Adults.,OPSUMIT, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease, pulmonary arterial hypertension associated with congenital heart disease with repaired shunts,in patients with WHO Functional class II, III or IV symptoms.
The drug product is supplied as a white to almost white, round, immediate-release dispersible tablet, debossed with a 2.5 on one side and with Mn on the other side.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
